|
![]() |
![]() University of Arkansas for Medical Sciences (UAMS) As the University of Arkansas for Medical Sciences (UAMS) Chancellor, Dan Rahn, M.D., leads Arkansas’ only academic health sciences center, which encompasses patient care, education, research and outreach resources at locations across the state. He became UAMS’ fourth chancellor Nov. 1, 2009. Dr. Rahn is a nationally recognized researcher, clinician and experienced administrator. He served as the president of the Medical College of Georgia and the senior vice chancellor for health and medical programs for the University System of Georgia before coming to UAMS. He began his professional career in 1979 at Yale University School of Medicine, where he was director of the Lyme Disease Program, director of clinical training in rheumatology and director of faculty practice for the Department of Internal Medicine. After earning his bachelor’s and medical degrees at Yale, Rahn completed his residency at Yale-New Haven Hospital and a postdoctoral fellowship in rheumatology at Yale. Dr. Rahn is a nationally known expert on Lyme disease. He served on several national committees for developing treatment and educational guidelines for the disease. This included sitting on a Centers for Disease Control/American College of Physicians panel for a Physicians Educational Initiative on Lyme Disease and a Lyme Disease Treatment Guideline Committee of the Infectious Disease Society of America. As a researcher, Dr. Rahn received federal funding for studying a treatment for early Lyme disease among other funded projects. He was an author of nearly 30 articles in scientific journals and 19 textbook chapters. Dr. Rahn was an editor for a Lyme disease textbook produced by the American College of Physicians. Four times during his clinical practice, he was listed in the annual America’s Top Doctors guide. As an administrator, Dr. Rahn also is nationally recognized for his work on work force shortages in the health professions. He is a board member of the Association of Academic Health Centers and led the AAHC Health Workforce Shortages Advisory Committee. He serves on the Association of American Medical Colleges Advisory Panel on Health Care. While at the Medical College of Georgia, he served on numerous state and local boards, including the Georgia Research Alliance, Georgia Cancer Coalition, Walton Rehabilitation Institute and Georgia Chamber of Commerce, and he was chairman of the Augusta Metro Chamber of Commerce. A native of Pennsylvania, Rahn and his wife, Lana, have three children, Jason, Rebecca and Zachary. |
![]() NCTR/FDA weida.tong.fda.hhs.gov Dr. Tong is a gifted computational chemist with broad expertise that spans the entire spectrum of computational methods in molecular modeling and bioinformatics applied to systems biology, predictive toxicology, and knowledge management. He is internationally recognized for his leadership in the areas of computer modeling and bioinformatics, serves as a Science Advisory Board (SAB) member for the Netherlands Toxicogenomics Center, and as a SAB member for the EU Framework Project on CarcinoGenomics. Weida received his B.S. in Chemistry (1983) and his Ph.D. in Polymer Chemistry (1990) from Fudan University in China. Weida’s efforts and leadership qualities have made a significant impact within FDA and worldwide. He has supervised the FDA-led community-wide MicroArray Quality Control Consortium, analyzing technical performance and practical utility of emerging molecular technologies; and coordinated the development of the Liver Toxicity Knowledge Base to address public health concerns related to drug-induced liver injury. He played a major leadership role in the conception, design, and development of numerous computational tools in bioinformatics, chemoinformatics, computational toxicology, biostatistics, and systems biology. His work and creativity have public health impacts in predictive systems toxicology and risk assessment. His research (>200 publications) is cataloged in eminent peer-reviewed journals. |
![]() Director of Informatics Myeloma Institute for Research and Therapy djjohann@uams.edu Dr. Johann is a physician/scientist, Associate Professor at UAMS and Scientific Director of the UAMS Genomics Sequencing Facility. His scientific focus concerns the application of advanced molecular profiling and high-throughput technologies for the characterization of molecular alterations in cancer cells. Areas of emphasis include next-gen sequencing (NGS), high-resolution identity-based mass spectrometry (proteomics), laser capture microdissection (LCM), bioinformatics, and cancer biology. Previously, he was an assistant investigator at the National Cancer Institute (NCI), Center for Cancer Research (CCR), in the Medical Oncology Branch in Bethesda, MD. Prior to attending medical school he worked as an engineer for the Unisys Corporation for six years, where he directed a team of five engineers on projects involving avionic and systems level (OS, compilers) software design and instrumentation. During this time he also earned a graduate degree in computer science with distinction from Hofstra University. Dr. Johann received his M.D., from Case Western and received a graduate with distinction honors for Computer Applications in Medicine. Following residency he became a postdoctoral research fellow at the NIH/NCI Lab of Pathology, under the mentorship of Dr. Lance Liotta, with a focus on clinical proteomics. He was twice selected for AACR Scholar-in-Training Awards for research work involving novel bioinformatics. Medical Oncology/Hematology fellowships were completed at NIH in the NCI and NHLBI. He has authored ~40 publications and contributed to three patents. |
Dr. Hatzis has over 20 years of experience in senior research and management roles in biocomputational techniques, systems biology modeling, genomic analysis and clinical diagnostics. He received his Ph.D. from the University of Minnesota and held several senior research roles in the biotechnology industry. He has been the cofounder of two startup companies specializing in bioinformatics tools development and in clinical diagnostics. He is currently in the faculty of Medical Oncology, Department of Medicine at the Yale School of Medicine. Dr. Hatzis had been an active member of the Biostatistics committee of FDA's Microarray QC program, co-investigator on the NCI Cancer Biospecimen Integrity program and co-investigator on serveral studies by Breast Cancer Foundations. Among his most significant contributions are the co-development with colleagues from MD Anderson of the RCB index, a continuous index of residual disease in breast cancer, and the development of a gene-expression based prognostic signature for patients treated with standard chemotherapy that accounts for phenotypic differences and integrates endocrine sensitivity, and chemotherapy response and resistance endpoints. Dr. Hatzis continues to be involved in the design of biomarker validation clinical studies and development of strategies for translating genomic diagnostic assays to clinical practice. His current research interests focus on developing methods to characterize the genetic and molecular heterogeneity of breast cancer subtypes and the implications it might have on response and resistance to treatment. A key area of interest is to develop methodology that integrates genomic level information of individual patients to lead to more focused treatment decisions tailored for the individual tumor. Dr. Hatzis is serving as academic editor on biomarker journals, has been a reviewer on NCI and NSF panes and is serving as ad-hoc reviewer on several bioinformatics and clinical journals. |
![]() |
|
![]() Dr. Arnaoutakis specializes in the treatment of aerodigestive and genitourinary cancers. He is the coordinator of the Disease Oriented Committee for Lung Cancer Research in the Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. He is an active member of the SWOG cooperative group (formerly the Southwest Oncology Group), the American Society of Clinical Oncology (ASCO) and the International Association for the Study of Lung Cancer (IASLC). |
Dr. Xiao received his bachelor in biology from Xiamen University in 1989 and master in genetics from the Institute of Microbiology, Chinese Academy of Science in 1992. Later on, he moved to United States and finished Ph. D program in molecular genetics form the Medical College of Wisconsin in 1997 and master program in computer science from Marquette University in 1998. From 1998 to 2005, Dr. Xiao was bioinformatics scientist in GeneLogic, MetriGenix, and Celera Genomics. Since 2005, he joined the National Institute of Health as a contractor and then as a staff scientist at Center for Cancer Research, National Institute of Cancer. In Dec, 2014, Dr. Xiao joined Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Food and Drug Administration. Dr. Xiao has numerous publications in peer-reviewed journals such as Nature, PNAS, N. Engl. J. Med, and Cancer Cell. In 2010, he received the NIH director award and NIH merit award for his contribution in Lymphoma Leukemia Molecular Profiling Program. During his early career in industry, Dr. Xiao defined and developed IT infrastructure and software/database solutions for genomics and microarray data. His recent focus is to develop informatics tools in supporting next generation sequencing technology for intramural research at the NIH for various applications such as, genome assembly, ChIP-Seq, RNA-Seq, Exome-Seq and digital gene expression. |
![]() |
Mary Yang is an Associate Professor of Information Science at UALR and Director of the joint UALR/UAMS Bioinformatics Program. Mary Yang received the MS, MSECE and Ph.D. degrees from Purdue University and had postdoctoral training from NIH. She was the founding Editor-in-Chief of the International Journal of Computational Biology and Drug Design and is on the editorial board of the Journal of Supercomputing and the International Journal of Pattern Recognition and Artificial Intelligence. Dr. Yang's main research interest is to develop functional genomics and systems biology-based approaches to understanding the molecular mechanisms underlying complex diseases such as cancer. |
![]() |